- Home
- CHI vs AMLX Comparison
CHI vs AMLX Comparison
Compare CHI & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHI
- AMLX
- Stock Information
- Founded
- CHI 2002
- AMLX 2014
- Country
- CHI United States
- AMLX United States
- Employees
- CHI N/A
- AMLX N/A
- Industry
- CHI Investment Managers
- AMLX Biotechnology: Pharmaceutical Preparations
- Sector
- CHI Finance
- AMLX Health Care
- Exchange
- CHI Nasdaq
- AMLX Nasdaq
- Market Cap
- CHI 826.2M
- AMLX 749.9M
- IPO Year
- CHI N/A
- AMLX 2022
- Fundamental
- Price
- CHI $10.79
- AMLX $13.22
- Analyst Decision
- CHI
- AMLX Strong Buy
- Analyst Count
- CHI 0
- AMLX 7
- Target Price
- CHI N/A
- AMLX $14.86
- AVG Volume (30 Days)
- CHI 186.2K
- AMLX 2.0M
- Earning Date
- CHI 01-01-0001
- AMLX 11-06-2025
- Dividend Yield
- CHI 9.90%
- AMLX N/A
- EPS Growth
- CHI N/A
- AMLX N/A
- EPS
- CHI N/A
- AMLX N/A
- Revenue
- CHI N/A
- AMLX N/A
- Revenue This Year
- CHI N/A
- AMLX N/A
- Revenue Next Year
- CHI N/A
- AMLX N/A
- P/E Ratio
- CHI N/A
- AMLX N/A
- Revenue Growth
- CHI N/A
- AMLX N/A
- 52 Week Low
- CHI $9.70
- AMLX $2.60
- 52 Week High
- CHI $11.61
- AMLX $13.07
- Technical
- Relative Strength Index (RSI)
- CHI 72.71
- AMLX 83.84
- Support Level
- CHI $10.59
- AMLX $11.42
- Resistance Level
- CHI $10.70
- AMLX $12.25
- Average True Range (ATR)
- CHI 0.09
- AMLX 0.61
- MACD
- CHI 0.03
- AMLX 0.23
- Stochastic Oscillator
- CHI 97.12
- AMLX 97.37
About CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.